Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.

Clin Vaccine Immunol

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA

Published: September 2014

Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178570PMC
http://dx.doi.org/10.1128/CVI.00263-14DOI Listing

Publication Analysis

Top Keywords

levels years
8
vaccine booster
8
anti-hbs levels
8
participants detectable
8
detectable anti-hbs
8
levels ≥10
8
≥10 miu/ml
8
hepatitis
5
levels
5
hepatitis virus
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!